A recently published study by FMI expects the global common warts market to augment at a 3.6% CAGR from 2023 to 2033. By the end of the said assessment period, a valuation of US$ 1,100 Million is expected for the market. The increase in pharmaceutical R&D activity for efficient and focused treatment of common warts.
The global genital warts (condyloma acuminatum) market is predicted to be worth US$ 1.87 billion in 2023, rising to US$ 3 billion by 2033 at a CAGR of 4.84%.The global market is expected to benefit from government initiatives and increasing financing for cancer research. The rising expenditure on R&D connected with.
/PRNewswire/ Lytix Biopharma ("Lytix") (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company, today releases its fourth quarter and second half.